India’s pharmaceutical exports stood at USD 30.47 billion in 2024–25, registering a growth of 9.4 percent over the previous year, supported by a strong manufacturing base and expanding global outreach,
said Commerce Secretary Rajesh Agrawal.
The Commerce Secretary also highlighted that India’s domestic pharmaceutical market is currently estimated at around USD 60 billion, with a projection to double to approximately USD 130 billion by 2030.
He underlined that India is today the world’s third-largest pharmaceutical producer by volume and fourteenth by value, with more than 3,000 companies, 10,500 manufacturing units and over 60,000 generic brands across 60 therapeutic areas.
Indian medicines reach over 200 markets worldwide, with more than 60 percent of exports going to stringent regulatory destinations. The United States accounts for about 34 percent, while Europe accounts for around 19 percent of India’s pharmaceutical exports.
The Commerce Secretary also underlined the vision of Prime Minister Narendra Modi to position India as a trusted global trade partner and to expand India’s share in global pharmaceutical trade, thereby enabling wider access to quality and affordable healthcare across the world.
One-day Regional Chintan Shivir on Pharmaceutical Exports, organised by the Department of Commerce, Government of India, in collaboration with the Pharmaceutical Export Promotion Council of India (PHARMEXCIL), brought together policymakers, regulators, industry representatives, exporters including MSMEs, Indian missions abroad and technical experts to deliberate on key issues shaping India’s pharmaceutical export ecosystem.
